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Sialic acid is the receptor determinant for the human parainfluenza virus type 3 (HPF3) hemagglutinin–neuraminidase (HN)
glycoprotein, the molecule responsible for binding of the virus to cell surfaces. In order for the fusion protein (F) of HPF3 to
promote membrane fusion, HN must interact with its receptor. In addition to its role in receptor binding and fusion promotion,
the HPF3 HN molecule contains receptor-destroying (sialidase) activity. The putative active sites are in the extracellular
domain of this type II integral membrane protein. However, HN is not available in crystalline form; the exact locations of these
sites, and the structural requirements for binding to the cellular receptor, which has not yet been isolated, are unknown. Nor
have small molecular synthetic inhibitors of attachment or fusion that would provide insight into these processes been
identified. The strategy in the present study was to develop an assay system that would provide a measure of a specific step
in the viral cycle—functional interaction between viral glycoproteins and the cell during attachment and fusion—and serve
to screen a variety of substances for inhibitory potential. The assay is based on our previous finding that CV-1 cells
persistently infected (p.i.) with HPF3 do not fuse with one another but that the addition of uninfected CV-1 cells, supplying the
critical sialic acid containing receptor molecules that bind HN, results in rapid fusion. In the present assay two HeLa cell
types were used: we persistently infected HeLa-LTR-bgal cells, assessed their fusion with uninfected HeLa-tat cells, and then
quantitated the b-galactosidase (bgal) produced as a result of this fusion. The analog a-2-S-methyl-5-N-thioacetylneuraminic
acid (a-Neu5thioAc2SMe) interfered with fusion, decreasing bgal production by 84% at 50 mM and by 24% at 25 mM. In
beginning to extend our studies to different types of molecules, we tested an unsaturated derivative of sialic acid,
2,3-dehydro-2-deoxy-n-acetyl neuraminic acid (DANA), which is known to inhibit influenza neuraminidase by virtue of being
a transition-state analog. We found that 10 mM DANA inhibited neuraminidase activity in HPF3 viral preparations. More
significantly, this compound was active in our assay of HN–receptor interaction; 10 mM DANA completely blocked fusion and
bgal production, and hemadsorption inhibition by DANA suggested that DANA blocks attachment. In plaque reduction assays
performed with the compounds, the active analog a-Neu5thioAc2SMe reduced plaque formation by 50% at a 50 mM
concentration; DANA caused a 90% inhibition in the plaque reduction assay at a concentration of 25 mM. Our results indicate
that specific sialic acid analogs that mimic the cellular receptor determinant of HPF3 can block virus cell interaction and that
an unsaturated n-acetyl-neuraminic acid derivative with affinity to the HN site responsible for neuraminidase activity also
interferes with HN–receptor binding. Strategies suggested by these findings are now being pursued to obtain information
regarding the relative locations of the active sites of HN and to further elucidate the relationship between the receptor-
binding and receptor-destroying activities of HN during the viral life cycle. The quantitative assay that we describe is of
immediate applicability to large-scale screening for potential inhibitors of HPF3 infection in vivo. © 1999 Academic Press
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iINTRODUCTION
The envelope of HPF3 contains two viral glycoproteins
esignated HN (hemagglutinin–neuraminidase) and F
fusion protein). Attachment of the virus to the host cell is
nitiated through interaction of HN with the sialic acid
ontaining cell surface receptors. The ensuing fusion of
he viral envelope with the cellular membrane, resulting
n the release of the nucleocapsid into the cytoplasm, is
ediated by F. However, in the case of HPF3, and some
ther paramyxoviruses, both HN and F are involved in
embrane fusion. Cofunction of both glycoproteins was
1 These two authors contributed equally to the work.
2 To whom correspondence and reprint requests should be ad-iressed.
57ound to be necessary for syncytium formation (Horvath
t al., 1992; Hu et al., 1992; Lamb, 1993; Moscona and
eluso, 1991), and it has been proposed that interaction
f HN with the receptor triggers the conformational
hange in F required for its fusion promoting activity
Lamb, 1993). By virtue of its N (neuraminidase) moiety,
N also has a receptor-destroying potential, which plays
role in the spread of infection. Comparison in this
aboratory of HPF3 HN variants with mutations in N have
emonstrated the dependence of viral release on the
evel of receptor-destroying neuraminidase activity (Hu-
erman et al., 1995).
An assay system that would quantify functional viral
N–receptor contact and allow easy screening for inhib-
tory compounds was suggested by the properties of our
n vitro model for persistent HFP3 infection (Moscona
0042-6822/99 $30.00
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58 LEVIN PERLMAN ET AL.nd Galinski, 1990; Moscona and Peluso, 1991). CV-1
ells infected at high multiplicity of infection (m.o.i.) do
ot form syncytia because their surface is depleted of the
ialic acid receptor determinant necessary to interact
ith HN, but have the ability to fuse with uninfected cells
Moscona and Galinski, 1990; Moscona and Peluso,
991). In order to obtain a more sensitive and quantitative
ssay for fusion we now used two HeLa cell types, one
ossessing the gene for b-galactosidase (lacZ) under
he control of the HIV LTR and one expressing HIV tat
rotein. Once fusion between the two cell populations
ccurs, tat from one transactivates lacZ expression in the
ther population of cells, leading to the production of
-galactosidase (bgal).
In the present study we show that this particular assay
an be used to assess HN–receptor interaction during
he binding and fusion processes and to address func-
ional questions about HN. We began by examining the
ossibility that compounds that mimic the sialic acid
oiety of the cellular receptor for HPF3 would block
N–receptor interaction. The relative inhibitory action of
uch analogs should provide information about the struc-
ure of the binding site of HN, as well as permit the
esign of low-molecular-weight inhibitors of HPF3 infec-
ion and pathogenesis.
Using our cell fusion assay as one indication of HN–
eceptor interaction during binding between HN and
eceptor and cell fusion, we analyzed synthetic sialic
cid analogs for their ability to inhibit fusion between
ersistently infected (p.i.) cells and uninfected cells. The
aturally occurring sialic acid, Neu5Ac, was modified at
articular sites to determine which functional groups
ay be important in recognition and binding of HN to
ialic acid-containing molecules. The analogs were also
nalyzed for their ability to inhibit viral infection as de-
ermined by a standard plaque assay. We found that the
nalog a-2-S-methyl-5-N-thioacetylneuraminic acid
a-Neu5thioAc2SMe), which blocked fusion between
ersistently infected and uninfected cells, also inhibited
laque formation.
Our studies also included 2,3-dehydro-2-deoxy-n-
cetylneuraminic acid (DANA), an unsaturated sialic acid
erivative, which is an inhibitory transition-state analog
f influenza virus neuraminidase. We found that this
ompound inhibited the neuraminidase activity in HPF3
iral preparations. In our quantitative assay, DANA
locked the fusion of p.i. cells with uninfected cells. The
bility of DANA to interfere with viral entry was indicated
y its inhibitory effect in the plaque reduction assay.
lockade of attachment of erythrocytes to p.i. cells by
ANA during hemadsorption supported the postulate
hat DANA’s interference with fusion in the quantitative
ssay was due to interference with receptor interaction.
The results demonstrate the broad utility of the herein
escribed quantitative fusion assay for assessing recep-or interaction, for identifying potential inhibitors of para- Mnfluenza virus type 3 infection, and for uncovering new
nformation about the nature of HPF3–receptor interac-
ion.
RESULTS/DISCUSSION
evelopment of the fusion assay
To further our understanding of the interaction be-
ween the HN glycoprotein and its sialic acid-containing
eceptor, we developed a quantitative assay that allows
s to test the ability of molecules to interfere with the
nteractions between the viral glycoproteins and the tar-
et cell that are required for fusion. To set up this assay,
e took advantage of the fusion properties of our in vitro
odel of persistent infection with HPF3 (Moscona and
alinski, 1990; Moscona and Peluso, 1991). Persistent
nfection with HPF3 is readily established in cultured
V-1 cells by infection of cell monolayers at high multi-
licity of infection (Moscona and Galinski, 1990). While
he p.i. cells do not fuse with one another, they undergo
apid and complete fusion when seeded with uninfected
ells. We showed that the lack of fusion between the p.i.
ells was due to an insufficiency of sialic acid-containing
eceptors for the viral HN glycoprotein and that their
usion with uninfected cells results directly from the
nteraction of HN with receptors available on the unin-
ected cells (Moscona and Peluso, 1991).
To quantitate fusion we used two HeLa cell types, one
HeLa-CD4-LTR-bgal) containing the b-galactosidase
ene under control of the HIV LTR and another (HeLa-tat)
xpressing the HIV tat protein. Fusion between the two
ifferent cell types leads to the production of b-galacto-
idase, which is then quantitated. These HeLa cell types
ere used previously to assess cell fusion mediated by
xpressed individual HPF3 proteins (Tanaka and Galin-
ki, 1995). A somewhat different approach (using T7 RNA
olymerase expressed by recombinant vaccinia virus in
ne cell population to drive lacZ synthesis in the other)
as applied to demonstrate fusion mediated by HIV
nvelope proteins (Nussbaum et al., 1994) and by ex-
ressed HPF3, NDV, and SV5 proteins (Bagai and Lamb,
995) and to assess the relationship between the surface
ensity of expressed HPF3 HN protein and the extent of
PF3 F protein promoted fusion (Dutch et al., 1998). For
ur experiments, we established a persistent infection by
PF3 in HeLa-CD4-LTR-bgal cells and assessed the
usion of these cells with uninfected HeLa-tat cells as a
easure of interaction between HN on p.i. cells and
ialic acid receptor on uninfected cells.
In the present assay system, HeLa-CD4-LTR-bgal
ells persistently infected with HPF3 were seeded in
6-well plates and allowed to adhere overnight. Unin-
ected HeLa-tat cells were then added and bgal activity,
esulting from the fusion between the two cell types, was
etermined in lysates as described under Materials and
ethods.
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59HUMAN PARAINFLUENZA 3 HN–RECEPTOR INTERACTIONTo explore the sensitivity of the assay system, we
aried the number of uninfected cells (added to a con-
tant number of adherent p.i. cells) and followed the time
ourse of bgal activation (Fig. 1). Fusion, assessed mi-
roscopically, was complete at 2 h; b-galactosidase ac-
ivity became appreciable at 3 h, and its ensuing rise
curves 1–4, Fig. 1) was directly related to the number of
ninfected cells added. This cell number-dependent gra-
ation in the extent of fusion was most clearly reflected
y bgal activity measured after the fourth hour of incu-
FIG. 1. Time course of bgal activation resulting from the fusion of
arying numbers of uninfected HeLa-tat cells with the adherent layer of
.i. HeLa-CD4-LTR-bgal cells. bgal activity (ordinate) was determined
fter the indicated hours of incubation (abscissa). The numbers of
ninfected cells added at time 0 were 0.38 3 104, 0.75 3 104, 1.5 3 104,
nd 3 3 104 for graphs 1, 2, 3, and 4, respectively. The adherent layer
ontained 3 3 104 cells.
FIG. 2. Dose–responsive inhibition of HN–receptor interaction by a
ilutions of antibody were added to the adherent layer of p.i. cells an
olumns) was determined immediately after microscopic assessment of fusioation. Based on experiments like those in Fig. 1, bgal
as routinely determined 6 h after the addition of 3 3 104
ninfected cells to 3 3 104 adherent p.i. cells. Wells with
dherent p.i. cells to which no uninfected cells were
dded served as controls.
Experiments designed to confirm the specificity of the
ssay included pretreatment of the uninfected cells with
euraminidase to remove sialic acid prior to incubation
ith the p.i. cells. This (as shown previously for CV-1
ells (Moscona and Peluso, 1991)) prevented the fusion
f the uninfected cells with the p.i. HeLa cells. Accord-
ngly, bgal activity remained in the background range,
hereas the control treatment, preincubation at pH 6.0 in
he absence of neuraminidase, resulted in activities sim-
lar to those obtained without any pretreatment. For this
xperiment, prior to their addition to p.i. cells, uninfected
ells were incubated at pH 6.0 without or with 0.5 units of
euraminidase (Clostridium perfringens) for 30 min at
7°C or received no pretreatment. The bgal activity val-
es, averaged for replicate wells (10 for each experimen-
al condition) in each experiment and given as means
SD of results of three separate experiments, are as
ollows: preincubation without neuraminidase, 1.87 6
.15; preincubation with neuraminidase, 0.07 6 0.03; no
retreatment, 1.70 6 0.44.
An important confirmation of specificity was to add
nti-HPF3 antiserum (which contains anti-HN antibody)
r anti-HN monoclonal antibody to the assay system.
hese antibodies inhibited, in a dose–responsive fash-
on, the interaction between viral glycoprotein and cell
hat is required for fusion. This inhibition is demonstrated
y decrease of fusion and of bgal activity (see Fig. 2).
he highest levels of antibody, which completely blocked
usion of p.i. cells with uninfected cells, decreased bgal
alues to baseline levels. With a decreasing amount of
ntibody, fusion became more apparent and bgal trans-
treatment. Standard amounts of uninfected cells plus the indicated
bated under standard conditions for 6 h. bgal activity (see height ofntibody
d incun (see photomicrographs).
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60 LEVIN PERLMAN ET AL.ctivation increased correspondingly. While this study
annot show definitively which components of the inter-
ction are inhibited by the antibodies, the results support
he notion that fusion and bgal activity in the assay relate
uantitatively to viral protein interactions with the target
ell.
pplication of the quantitative fusion assay to the
tudy of sialic acid receptor analogs
It was shown for influenza A virus that several analogs
f N-acetylneuraminic acid can bind HA and inhibit virus
inding to receptor at 4°C (Itoh et al., 1995; Machytka et
l., 1993). If such analogs are to be useful for inhibiting
nfection, they must act at 37°C, and at this temperature
hey may be degraded by neuraminidase. In the case of
nfluenza, replacing oxygen by sulfur at the C2 position
where natural sialic acid is linked to additional carbo-
ydrates and cleavage by neuraminidase occurs) or re-
oval of the acyl group on carbon 5 made the molecules
esistant to neuraminidase (Itoh et al., 1995). These find-
ngs, and observations on the effect of substitutions at
arbon 2 and 5 on the analogs’ binding affinity to HA
Kelm et al., 1992), influenced the choice of analogs for
ur studies. The structures of the analogs that we de-
cribe here, compared to the natural sialic acid moiety of
he receptor, are shown in Fig. 3.
Figure 4 shows the effect of the various sialic acid
nalogs on the level of fusion between persistently in-
ected HeLa-CD4-LTR-bgal and uninfected HeLa-tat
ells as measured by bgal activity. It may be seen that
-Neu5Ac2Me, which is identical to N-acetylneuraminic
FIG. 3. Structures of the synthetic sialic acid analogs compared to
he natural molecule.cid except for the glycosidic methyl group at C2 (Kuhn dt al., 1966), did not decrease fusion significantly. In
ontrast, the analog a-Neu5thioAc2SMe (a-2-S-methyl-5-
-thioacetylneuraminic acid), which differs from
-acetylneuraminic acid by containing an S-methyl
roup for the glycosidic group at the C2 position and
-thioacetyl at C5 (Isecke and Brossmer, 1994), de-
reased fusion between the two cell populations by 80%
t 50 mM; the smaller, 24% inhibition at 25 mM indicates
ose–responsive behavior. In this analog, the S substi-
ution on C2 conferred neuraminidase resistance (Itoh et
l., 1995). However, the S on C5 as well as on C2 may
ave also enhanced binding to HN; this same analog
as found to be most effective in inhibiting influenza
irus binding to fetuin at 4°C (Itoh et al., 1995).
The third analog tested, a-Neu5NH2-2Me, contains an
-glycoside at C2 and is lacking the acyl group at carbon
. While this lack conferred resistance to influenza neur-
minidase (Itoh et al., 1995), the C5-acyl group was found
o be essential for binding to HA (Kelm et al., 1992). As
een in Fig. 4, this analog did not inhibit HN–receptor
nteraction in our fusion assay. It is possible that in the
ase of HPF3, too, removal of the C5 acyl group is
bolishing not only neuraminidase susceptibility but also
inding ability.
se of the quantitative fusion assay to assess the
ffect of DANA
We next began to use the cell fusion assay to study the
elationship between the receptor-binding and the re-
eptor-cleaving functions of HN. In addition to the roles
f the HPF3 HN in receptor binding and fusion promo-
FIG. 4. Effect of the sialic acid analogs on the degree of fusion
etween p.i. HeLa-CD4-LTR-bgal and uninfected HeLa-tat cells. The
ndicated analogs were added to p.i. cells immediately before the
ddition of the uninfected cells. bgal activity was determined after 6 h
f incubation. The results, at 50 or 25 mM analog concentrations, are
iven as the percentage inhibition, i.e., relative to analog-free controls
un simultaneously on the same plates. Each column is the mean (bar
enotes 1 SD) of results of three or four experiments.
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61HUMAN PARAINFLUENZA 3 HN–RECEPTOR INTERACTIONion, the HN molecule has neuraminidase (or receptor-
leaving) activity. Our previous work has shown that this
euraminidase activity of HN is important for release of
PF3 virus particles from the surface of the infected cell.
his neuraminidase function, release of virus particles
rom the surface of the infected cell, allows the virus to
egin a new round of infection.
In contrast to the role of HN’s neuraminidase in virus
elease, there is no evidence to date that neuraminidase
lays a role in entry. While the binding function of HN and
he neuraminidase function of HN are on the same mol-
cule in this virus, the crystal structure has not been fully
etermined despite efforts to crystallize the molecule
Laver et al., 1989; Murti et al., 1993; Takimoto et al., 1992)
nd it is not certain whether these two functions reside
n adjacent or distant sites on the molecule (Gorman et
l., 1990, 1991; Iorio et al., 1989; Lyn et al., 1991;
cGinnes et al., 1993; Portner, 1981; Portner et al., 1987;
ergel et al., 1993; Sheehan and Iorio, 1992; Thompson
nd Portner, 1987).
To address the separate functions of binding and en-
yme activity of the HN molecule, we studied the effects
n binding and enzyme activity of an unsaturated sialic
cid derivative of N-acetylneuraminic acid, DANA. DANA
s known to inhibit influenza neuraminidase by virtue of
eing a transition-state analog and has been shown to
nhibit the activity of the neuraminidases of HPF2 (Holzer
t al., 1993), Sendai virus (Portner, 1981), NDV (Portner,
981), and mumps virus (Waxham and Wolinsky, 1986). In
ddition, Iorio et al. (1989) found that the action of mono-
lonal antibodies whose binding to NDV HN inhibits
FIG. 5. Effect of DANA on activity of HPF3 neuraminidase. The results
re given as percentage inhibition of enzyme activity at the indicated
oncentrations of DANA. Neuraminidase activities were determined
sing HPF3 virions at pH 4.7, using a mixture of 2,3- and 2,6-neurami-
yllactose as substrate, for 30 min under conditions of substrate ex-
ess.euraminidase activity was blocked by DANA. For HPF2 ind mumps, DANA was found to have a K i of 10
25 (Holzer
t al., 1993) and of 4 3 1024 (Waxham and Wolinsky,
986), respectively. For Sendai virus and NDV, 0.1 mM
as the lowest DANA concentration at which complete
nhibition of enzyme activity was attained (Portner, 1981).
igure 5 shows that DANA inhibits the activity of HPF3
euraminidase; at a 10 mM concentration, the inhibition
s about 75% and at a concentration of 1 mM, the activity
s reduced by only about 35%. Thus, HPF3 neuramini-
ase is less effectively inhibited by DANA than the
aramyxovirus neuraminidases studied previously.
Figure 6 shows the effect of DANA on the extent of
usion between persistently infected HeLa LTR-bgal
ells and uninfected HeLa-tat cells. Surprisingly, we
ound that DANA works extremely well, and in fact more
ffectively than the sialic acid analog compounds we
ested, at interfering with the HN–receptor interaction
equired for fusion. DANA decreased fusion between the
wo cell populations by 98% at 25 mM, 80% at 5 mM, and
8% at 1.5 mM.
nhibition of receptor binding by DANA in a
emadsorption assay
The effect of DANA on receptor binding was assessed
y a hemadsorption assay to test the ability of DANA to
nterfere with the adherence of erythrocytes to persis-
ently infected cells. This experiment was designed to
etermine whether DANA’s ability to interfere with cell
usion could be due to its effect on neuraminidase enzy-
atic function or due to interference with receptor inter-
ction. To test this, we assessed binding to erythrocytes
t 4°C, under conditions in which the neuraminidase
nzyme is inactive, but the binding function is intact. This
FIG. 6. Effect of DANA on the degree of fusion between p.i. HeLa-
D4-LTR-bgal and uninfected HeLa-tat cells. DANA, at concentrations
anging from 0.2 to 25 mM, was added to p.i. cells immediately before
he addition of the uninfected cells. bgal activity was determined after
h of incubation. The results are given as percentage inhibition, i.e.,
elative to DANA-free controls run simultaneously on the same plates.
ach column is the mean (bar denotes 1 SD) of results of four exper-ments.
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62 LEVIN PERLMAN ET AL.ssay also effectively separates the step of attachment
rom the subsequent steps in the fusion process. Mono-
ayers of p.i. cells were incubated with human erythro-
ytes at 4°C for 120 min in the presence of various
oncentrations of DANA. Table 1 shows that DANA ef-
ectively blocks attachment at 4°C as assessed by the
dherence of erythrocytes to the p.i. monolayer. The
ANA effect on blocking hemadsorption is concentration
ependent, with complete inhibition of erythrocyte bind-
ng at a concentration of 1.6 mM. The range of DANA
oncentrations that inhibit hemadsorption is similar to
he concentrations that inhibit fusion in the quantitative
usion assay. Erythrocytes may not be representative of
ost cells and may not contain the same complement of
eceptors or membrane composition as authentic target
ells. Nevertheless, these results suggest that DANA’s
bility to interfere with cell fusion was due to its interfer-
nce with receptor interaction rather than to its neur-
minidase inhibition and support the notion that DANA
locks attachment.
nhibition of viral entry and replication by sialic acid
eceptor analogs and by DANA
The effects of the sialic acid analogs on viral entry and
eplication were assessed by a plaque reduction test.
-Neu-5thio-Ac2SMe inhibited plaque formation by 60
nd 10% at concentrations of 50 and 25 mM, respectively.
he analogs that were ineffective in the fusion assay
Neu5Ac2Me and Neu5NH2Me) did not inhibit plaque
ormation.
TABLE 1
Effect of DANA on Erythrocyte Binding (HAD)
to Persistently Infected Cells
DANA concentration
(mM)
HAD
(erythrocyte binding)
25 0
12.5 0
6.2 0
3.1 0
1.6 0
0.8 1
0.4 11
0.2 111
0.1 111
0 111
Note. DANA, in concentrations ranging from 0.2 to 25 mM, was
dded to a confluent monolayer of p.i. cells immediately before the
ddition of a 1% solution of human erythrocytes. Hemadsorption activity
as determined after 2 h of incubation at 4°C. The results are given as
score of 0 to 111 erythrocyte binding, with 111 being complete
overage of the p.i. monolayer by erythrocytes as seen in the absence
f DANA. Each data point derives from the identical results of four
xperiments.We tested whether the ability of DANA to interfere with mN–receptor interaction in the fusion assay would be
onfirmed by an ability to block viral entry as measured
y the plaque reduction test. Figure 7 shows that DANA
educed the number of plaques formed in a dose-depen-
ent manner. This inhibition, 90% at a concentration of 25
M, was more effective than that of the sialic acid
nalogs.
We determined whether DANA exerts any effect after
he adsorption period or whether it blocks binding only
uring the adsorption period. Either the addition of DANA
o the plaque reduction test was delayed until 90 min,
ust prior to the addition of the agarose overlay, or DANA
as added at the time of infection but removed by wash-
ng at 90 min. Table 2 shows that the reduction of plaque
umber by DANA addition at the time of infection was not
ltered significantly by its removal at 90 min and that
ddition of DANA at 90 min caused no significant reduc-
FIG. 7. Effect of DANA on viral entry and replication. Cells were
nfected with HPF3, with the simultaneous addition of DANA in con-
entrations ranging from 0.4 to 50 mM. Plaque formation proceeded
nder an agarose overlay for 48 h, and plaques were visualized and
ounted. The results are given as percentage reduction in plaque
umber, i.e., relative to DANA-free controls run simultaneously. Each
olumn is the mean of results of four experiments.
TABLE 2
Effect of Timing of DANA Addition on Inhibition
of Viral Entry and Replication
Time of DANA addition
% reduction of
plaque number
0 min 76.0 6 1.3
0 min, removed at 90 min 67.3 6 5.8
90 min 1.7 6 5.7
Note. Cells were infected with HPF3. DANA (25 mM) was added
mmediately and remained present (line 1) or was removed at the end
f the 90-min adsorption period (line 2) or was added at 90 min only
line 3), just before application of the agarose overlay. Plaque formation
roceeded for 48 h, and plaques were visualized and counted. Results
re presented as percentage reduction in number of plaques, i.e.,
elative to DANA-free controls run simultaneously. The values are
eans (6SD) of results of four to seven experiments.
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63HUMAN PARAINFLUENZA 3 HN–RECEPTOR INTERACTIONion in plaque number. This experiment, showing that
ncubation with DANA during the adsorption period
lone suffices for the inhibitory effect, provides support
or the notion that DANA acts at the stages of viral
inding and/or entry.
uture implications
The fusion assay described here for the purpose of
valuating interaction of viral glycoproteins with the cell
s carried out with a stable, standard source of material;
.i. cell lines provide the HN and F proteins, and unin-
ected cell lines are the receptor donors. These materials
re completely reproducible from experiment to experi-
ent and in different laboratories. Overlay cells as a
ource of receptor, and inhibitory compounds to be
ested, can be added using any concentration or timing
esired. This assay, rendered quantitative by use of a
ublished b-galactosidase reporter system, is thus
niquely suited to large-scale screening for synthetic
ompounds that may interfere with viral entry. While
revious routine methods of screening for antiviral
gents (for example, plaque-reduction assays) reflect the
nd result of several steps that fall between entry and
elease, the present assay permits quantitative study of
he early, crucial steps of functional viral glycoprotein–
ell surface interaction. The hemadsorption assay can
est for interference with receptor binding, but lacks
uantitative resolving power and, furthermore, erythro-
ytes differ from authentic target cells in terms of the
omplement of receptors and membrane composition.
he present fusion assay, which is applicable to any cell
ine of choice and permits sensitive quantitation, thus
as greater utility as a method of screening for antiviral
gents.
Our results in this first study of the effect of synthetic
ialic acid analogs on HPF3 indicate that compounds
hat mimic the receptor determinant for HPF3 HN can
lock virus–cell interaction and may have the potential to
ounteract infection. For the influenza virus, X-ray crys-
allography studies yielded an atomic model for HA–
ialic acid interaction, which provides a rational basis for
esigning receptor analogs. No such structural model is
vailable for HPF3. However, the quantitative fusion as-
ay we describe in this paper facilitates screening a
ide range of compounds for their ability to block HN–
eceptor interaction. Thus, one should be able to obtain
nformation about the binding requirements (receptor
eterminants) of the viral HN and, at the same time,
dentify sialic acid analogs with the potential to inhibit
PF3 infection.
It should be noted that, for influenza virus, monomeric
ialic acid compounds, even those that blocked virus
inding to fetuin and were neuraminidase resistant,
ailed to inhibit plaque formation. Only the polymeric
orms of some of those analogs were effective in reduc- ing plaque formation (Itoh et al., 1995). Among these
olyacrylamide-based polymers, that of a-Neu5thio-
c2SMe (the active monomer in the present studies)
howed the most striking interference with the replica-
ion of several different strains of influenza virus; the
oncentration at which this polymer completely inhibited
laque formation was 1/100 of that required to inhibit HA
inding to fetuin (Itoh et al., 1995). We are thus planning
o extend these studies on HPF3 to test polymerized
orms of analogs for effectiveness in our fusion assay
nd examine their ability to block viral entry in the plaque
eduction test.
In our assay, the fusion between p.i. and uninfected
ells was also blocked by DANA, which is known to be a
ransition-state inhibitor of influenza virus neuramini-
ase. Although, as we now show, DANA can also inhibit
PF3 neuraminidase, this inhibition is unlikely to under-
ie the ability of this compound to block HN–receptor
nteraction in the fusion assay. Since the pH optimum of
PF3 neuraminidase is 4.7 (Moscona and Peluso, 1993),
t would exert only 1 to 9% of its maximal activity at the
hysiological pH of the fusion assay. In addition, 25% of
iral neuraminidase enzyme activity is still present at a
0 mM DANA concentration that completely blocks fu-
ion (compare Figs. 5 and 6). Most importantly, DANA
locks receptor binding in a hemadsorption assay at
°C, further indicating that DANA’s ability to block fusion
s due to interfering with HN–receptor interaction rather
han to inhibition of neuraminidase. While erythrocytes
re not entirely representative of host cells and may not
ontain all the same receptors or membrane compo-
ents, these results provide support for the notion that
ANA blocks attachment. The possibility that DANA may
lso exert an effect on steps in the fusion process sub-
equent to HN–receptor contact, such as HN–F interac-
ion, conformational changes in the viral glycoproteins,
nd F protein-mediated fusion of the lipid bilayers, re-
ains to be explored.
Since there is no crystallographic information on the
tructure of paramyxovirus HN, there is debate in the
iterature as to whether the receptor-binding and the
euraminidase activity sites of paramyxovirus HN mole-
ules are physically adjacent, remote, or in some way
ssociated with one another (Gorman et al., 1990, 1991;
orio et al., 1989; Portner, 1981; Portner et al., 1987; Shee-
an and Iorio, 1992). Resolution of this question awaits
etermination of the crystal structure of a paramyxovirus
N. Our results on DANA are pertinent here, because
hey indicate that the same small molecule can inhibit
PF3 neuraminidase and specifically block HN–receptor
nteraction during attachment and fusion.
We propose three possible interpretations of these
esults with DANA. First, the receptor binding and neur-
minidase enzyme sites on HN may be physically adja-
ent to one another, allowing one DANA molecule tonteract with both sites; second, binding of DANA to the
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64 LEVIN PERLMAN ET AL.euraminidase active site may induce an inactivating
hange in a distant binding site; and third, DANA mole-
ules may bind independently to two distinct functional
ites. These three interpretations yield hypotheses test-
ble in future experiments. Structurally distinct small
olecules will be used to derive further data about the
elative locations of the active sites on the HN molecule
nd about the relationship between receptor-binding and
eceptor-destroying activities of HPF3.
MATERIALS AND METHODS
Virus. Stocks of wildtype HPF3 were made in CV-1
ells from virus that was plaque-purified four times. Virus
as released after freeze–thawing 36 to 48 h postinfec-
ion and stored at 280°C. Virus titer was determined by
plaque assay (see below) with CV-1 cells.
Cells. HeLa-CD4-LTR-bgal cells and HeLa-tat cells
ere obtained through the AIDS Research and Refer-
nce Program, Division of AIDS, NIAID, NIH. HeLa cell
ines and CV-1 (African green monkey kidney) cells were
aintained with Eagle’s minimal essential medium sup-
lemented with 10% fetal bovine serum and antibiotics.
Sialic acid analogs and transition-state analog. The
ynthesis of analogs used in this study (for structures
ee Fig. 3) was performed as previously described
Isecke and Brossmer, 1994). The resistance of the ana-
ogs to influenza X-31 neuraminidase was tested accord-
ng to Itoh et al. (1995). DANA was purchased from Sigma
hemical Corp.
Cell fusion assay. HeLa-LTR-bgal cells were persis-
ently infected with HPF3, using our methods developed
or CV-1 cells (Moscona and Peluso, 1991, 1992), at a
ultiplicity of infection sufficient to infect all of the cells
n the culture (.5 PFU per cell). Under these conditions
o cell–cell fusion occurs. The presence of persistent
iral infection in the cells was documented by hemad-
orption positivity of the entire cell monolayer (Moscona
nd Peluso, 1992), release of infectious particles into the
upernatant fluid (Moscona and Galinski, 1990), and viral
rotein synthesis in metabolically labeled cells
Moscona and Galinski, 1990). To set up the fusion assay,
.i. HeLa-LTR-bgal cells were plated in 96 well plates.
fter 24 h, uninfected HeLa-tat cells (3 3 104 per well)
ere added to the adherent cells, and fusion was al-
owed to proceed for 6 h at 37°C. b-Galactosidase ac-
ivity was then measured as described (Nussbaum et al.,
994). The cells were lysed with NP-40 and mixed with
hlorophenol red-galactopyranoside. Absorbance was
easured at an OD of 590.
Assay of viral neuraminidase. Neuraminidase activities
ere determined by the thiobarbituric acid assay as
reviously described (Merz et al., 1981; Moscona and
eluso, 1993) using sucrose-gradient purified HPF3 viri-
ns. 2,3-Neuraminyllactose and 2,6-neuraminyllactose
ubstrates were purchased from Sigma Chemical Corp.Hemadsorption assay. Monolayers of p.i. cells were
ashed with cold medium lacking serum and then incu-
ated with human erythrocytes at 4°C for 120 min in the
resence of various concentrations of DANA. Nonadher-
nt cells were removed by washing with cold medium;
he extent of erythrocyte adsorption was estimated and
he plates were photographed through a phase-contrast
icroscope.
Plaque reduction assay. CV-1 cell monolayers grown in
lastic dishes of 3.5 cm in diameter were inoculated with
00 PFU of HPF3 and were incubated at 37°C in Eagle’s
inimum essential medium with intermittent rocking in
he presence of various concentrations of sialic acid
nalogs or DANA. After 90 min, minimum essential me-
ium containing 0.5% agarose was added to the dishes
nd incubated for 48 h. In some experiments, DANA
resent during the adsorption period was removed by
ashing three times in Eagle’s minimum essential me-
ium, and in parallel dishes DANA was absent during the
dsorption period and added to the cell monolayers just
rior to the addition of the agarose overlay. After the
garose overlay was removed, the cells were fixed with
0% formaldehyde in PBS and stained with a 1% crystal
iolet solution in methanol. Alternatively, we used an
mmunostaining method for plaque detection (Herold et
l., 1991). Briefly, after the agarose overlay was removed,
he cells were fixed with methanol, washed, and blocked
ith PBS/3% BSA. Cells were incubated sequentially with
olyclonal guinea pig anti-HPF3 antibody (BioWhittaker),
iotinylated goat anti-guinea pig IgG, and streptavidin–
-galactosidase 1:150 in PBS–BSA. Each incubation was
or 1–2 h at room temperature. After being washed, the
ells were incubated with substrate consisting of Bluogal
BRL) in KFeCn buffer until blue plaques were visualized.
he number of plaques in the control and experimental
ells was counted.
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